Picture of Vitrolife AB logo

VITR — Vitrolife AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Sweden's Vitrolife Q1 sales fall on currency effects

Overview

Sweden medical devices and genetic testing firm's Q1 sales rose 5% in local currencies, down 4% in SEK

Q1 net income and EPS were flat yr/yr at SEK 101 mln and SEK 0.74

Gross margin improved to 59.9% from 57.4% in Q1 last yr

Outlook

Vitrolife did not provide specific guidance or outlook for the current or future periods in its press release

Result Drivers

REGIONAL PERFORMANCE - Sales growth in local currencies was driven by 11% increase in Americas and 7% in APAC, while EMEA declined 1%

PRODUCT GROUPS - Consumables and Technologies sales rose 9% and 11% respectively in local currencies, while Genetics fell 1%

GROSS MARGIN IMPROVEMENT - Gross margin increased to 59.9% from 57.4% in Q1 last year

Company press release: ID:nWkr6RWbSK

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 RevenueSEK 807 mln
Q1 EPSSEK 0.74
Q1 Net IncomeSEK 101 mln
Q1 EBITDASEK 251 mln
Q1 EBITDA Margin31.10%
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell" The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy" Wall Street's median 12-month price target for Vitrolife AB is SEK150.00, about 40.4% above its April 22 closing price of SEK106.80 The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 33 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Vitrolife AB

See all news